Literature DB >> 2466593

Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.

S Bhakdi1, R Käflein, T S Halstensen, F Hugo, K T Preissner, T E Mollnes.   

Abstract

It has been assumed that S-protein (vitronectin) associates with terminal C5b-9 complement complexes only when the latter fail to attach to target lipid bilayers, thereby forming inactive fluid-phase SC5b-9 complexes. Using monoclonal anti-S-protein antibodies, we show here that a minor portion of C5b-9 complexes associated with both homologous and heterologous cells contain S-protein. This conclusion derives from Western blot analyses, from the sedimentation behaviour of solubilized S-protein, and from the fact that the protein co-immunoprecipitates with C5b-9(m). Association of S-protein with C5b-9(m) takes place primarily at the stage of C9-binding. An average of less than or equal to 0.4 moles of S-protein are estimated to be present per mole C5b-9(m). Hence, only a fraction of C5b-9 complexes contain S-protein. The function of cell-bound S-protein is unknown. Haemolytic titrations with purified components failed to demonstrate any protective effect of S-protein on the lysis of sheep or human erythrocytes by C5b-9. S-protein bound to complement-lysed homologous or heterologous cells is readily detectable by conventional immunocytochemical staining. We conclude that differentiation between tissue-deposited fluid-phase C5b-9 and membrane C5b-9 complexes cannot be made on the basis of immunohistological stainings for S-protein alone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2466593      PMCID: PMC1542007     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

Review 1.  Membrane attack complex of complement as a pathologic mediator.

Authors:  G Biesecker
Journal:  Lab Invest       Date:  1983-09       Impact factor: 5.662

Review 2.  Membrane damage by complement.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Biochim Biophys Acta       Date:  1983-08-11

3.  Electroimmunoassay-immunoblotting (EIA-IB) for the utilization of monoclonal antibodies in quantitative immunoelectrophoresis: the method and its applications.

Authors:  S Bhakdi; D Jenne; F Hugo
Journal:  J Immunol Methods       Date:  1985-06-12       Impact factor: 2.303

4.  Physicochemical characterization of human S-protein and its function in the blood coagulation system.

Authors:  K T Preissner; R Wassmuth; G Müller-Berghaus
Journal:  Biochem J       Date:  1985-10-15       Impact factor: 3.857

5.  Quantitation of spreading factor in human biologic fluids.

Authors:  M C Shaffer; T P Foley; D W Barnes
Journal:  J Lab Clin Med       Date:  1984-05

6.  A simple immunoradiometric assay for the terminal SC5b-9 complex of human complement.

Authors:  S Bhakdi; M Muhly
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

7.  Isolation of human serum spreading factor.

Authors:  D W Barnes; J Silnutzer
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

8.  Serum spreading factor (vitronectin) is present at the cell surface and in tissues.

Authors:  E G Hayman; M D Pierschbacher; Y Ohgren; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

9.  Monoclonal antibodies to human plasma protein X alias complement S-protein.

Authors:  D Jenne; F Hugo; S Bhakdi
Journal:  Biosci Rep       Date:  1985-04       Impact factor: 3.840

10.  Cell attachment on replicas of SDS polyacrylamide gels reveals two adhesive plasma proteins.

Authors:  E G Hayman; E Engvall; E A'Hearn; D Barnes; M Pierschbacher; E Ruoslahti
Journal:  J Cell Biol       Date:  1982-10       Impact factor: 10.539

View more
  27 in total

1.  What is clusterin?

Authors:  I B Fritz
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

2.  S protein binds to serum-treated agarose beads independently of complement activation and the formation of the terminal complement complex on the beads.

Authors:  G Hetland; P Garred; H B Pettersen; T E Mollnes; E Johnson
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

3.  Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies.

Authors:  R Würzner; H Xu; A Franzke; M Schulze; J H Peters; O Götze
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

4.  Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice.

Authors:  N A Boyd; A R Bradwell; R A Thompson
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

5.  C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.

Authors:  Regina Tavano; Luca Gabrielli; Elisa Lubian; Chiara Fedeli; Silvia Visentin; Patrizia Polverino De Laureto; Giorgio Arrigoni; Alessandra Geffner-Smith; Fangfang Chen; Dmitri Simberg; Giulia Morgese; Edmondo M Benetti; Linping Wu; Seyed Moein Moghimi; Fabrizio Mancin; Emanuele Papini
Journal:  ACS Nano       Date:  2018-05-23       Impact factor: 15.881

6.  Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives.

Authors:  L Biancone; G Monteleone; R Marasco; F Pallone
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

7.  Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.

Authors:  L Milis; C A Morris; M C Sheehan; J A Charlesworth; B A Pussell
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

8.  Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers.

Authors:  H Dauchel; P Joly; A Delpech; E Thomine; F Sauger; X Le Loet; P Lauret; F Tron; M Fontaine; J Ripoche
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Immunohistochemical localization of C3d fragment of complement and S-protein (vitronectin) in normal and diseased human kidneys: association with the C5b-9 complex and vitronectin receptor.

Authors:  M Okada; K Yoshioka; T Takemura; N Akano; N Aya; K Murakami; S Maki
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.